GLA Antikörper (AA 322-409)
Kurzübersicht für GLA Antikörper (AA 322-409) (ABIN7114447)
Target
Alle GLA Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 322-409
-
Verwendungszweck
- GLA antibody
-
Aufreinigung
- Immunogen affinity purified
-
Reinheit
- ≥95 % as determined by SDS-PAGE
-
Immunogen
-
Immunogen sequence: 322-409aa
Immunogen: galactosidase, alpha
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- WB: 1:500-1:5000, IHC: 1:20-1:200, IP: 1:500-1:5000
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- PBS with 0.02 % sodium azide and 50 % glycerol pH 7.3,
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handhabung
- Avoid repeated freeze / thaw cycles.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- -20°C for 12 months
-
Haltbarkeit
- 12 months
-
-
- GLA (Galactosidase, alpha (GLA))
-
Andere Bezeichnung
- GLA
-
Hintergrund
-
Synonyms: Alpha-galactosidase A|Alpha-D-galactosidase A|Alpha-D-galactoside galactohydrolase|Galactosylgalactosylglucosylceramidase GLA|Melibiase|GLA
Background: GLA, also named as Melibiase, Agalsidas and Alpha-galactosidase A, Belongs to the glycosyl hydrolase 27 family. It hydrolysis of terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids. Fabry disease is an X-linked lysosomal storage disorder resulting from the deficient activity of GLA. Enzyme replacement therapy(ERT) with GLA is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease.
-
Molekulargewicht
- 49 kDa
-
Gen-ID
- 2717
-
UniProt
- P06280
-
Pathways
- SARS-CoV-2 Protein Interaktom
Target
-